Repare Therapeutics Inc.
RPTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.01 | 0.28 | -0.08 |
| FCF Yield | -137.59% | -42.01% | -0.05% | -10.97% |
| EV / EBITDA | 0.30 | -1.75 | -25.96 | -4.39 |
| Quality | ||||
| ROIC | -62.16% | -48.64% | -14.38% | -31.74% |
| Gross Margin | 74.98% | 74.11% | 11.46% | -1,055.97% |
| Cash Conversion Ratio | 0.90 | 1.36 | -0.01 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -25.97% | 88.78% | 892.11% | – |
| Free Cash Flow Growth | 40.78% | -46,005.71% | 99.68% | -951.39% |
| Safety | ||||
| Net Debt / EBITDA | 0.92 | 0.94 | 8.65 | 3.05 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -604.12 | 43.13 | -28.25 | -95.95 |